Thymoctonan

Drug Profile

Thymoctonan

Alternative Names: FCE 25388; THF-gamma2; Thymic humoral factor; Thymic humoral factor gamma-2

Latest Information Update: 06 Dec 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacia Corporation
  • Developer Nonindustrial source; Pharmacia Corporation; Yeda
  • Class Antivirals; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; HIV infections; Viral infections

Most Recent Events

  • 27 Feb 2001 A preclinical study has been added to the Cancer pharmacodynamics filed
  • 30 Mar 2000 Discontinued-II for HIV infections treatment in France (Unknown route)
  • 30 Mar 2000 Discontinued-II for HIV infections treatment in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top